Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $36,523,319.58

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$445.21

▲ +4.57 (1.04%)

As of 05/17/2024 01:00 AM ET

Days: 30 | 90 | 365

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Secure Your Spot Now

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556
5/30/2023	Kristen Ambrose	CAO	Sell	289	$329.82	$95,317.98	6,838
5/30/2023	Stuart A. Arbuckle	COO	Sell	82	$329.82	$27,045.24	56,556
5/8/2023	Bastiano Sanna	EVP	Sell	2,850	$350.00	$997,500.00	32,038
5/8/2023	Jeffrey M. Leiden	Chairman	Sell	1,125	$349.00	$392,625.00	35,387
5/5/2023	Bastiano Sanna	EVP	Sell	422	$350.03	$147,712.66	34,888
5/5/2023	Jeffrey M. Leiden	Chairman	Sell	879	$349.56	$307,263.24	36,512
5/2/2023	Bastiano Sanna	EVP	Sell	1,622	$350.66	$568,770.52	38,091
5/2/2023	Jeffrey M. Leiden	Chairman	Sell	6,450	$349.89	$2,256,790.50	41,899
5/2/2023	Sangeeta N Bhatia	Director	Sell	580	$348.28	$202,002.40	4,628
4/27/2023	Reshma Kewalramani	CEO	Sell	3,317	$339.08	$1,124,728.36	126,652
4/12/2023	Bastiano Sanna	EVP	Sell	7,567	$326.70	$2,472,138.90	39,713
4/12/2023	Bruce I. Sachs	Director	Sell	21,300	$326.73	$6,959,349.00	41,210
4/4/2023	Bastiano Sanna	EVP	Sell	522	$315.81	$164,852.82	47,280
3/24/2023	Charles F. Wagner, Jr.	CFO	Sell	1,768	$305.38	$539,911.84	49,611
3/17/2023	Charles F. Wagner, Jr.	CFO	Sell	2,000	$296.39	$592,780.00	51,379
3/16/2023	Bastiano Sanna	EVP	Sell	2,746	$300.59	$825,420.14	49,268
3/13/2023	Charles F. Wagner, Jr.	CFO	Sell	2,666	$293.83	$783,350.78	53,379
3/10/2023	Charles F. Wagner, Jr.	CFO	Sell	2,088	$289.61	$604,705.68	56,045
2/27/2023	Kristen Ambrose	CAO	Sell	1,207	$287.55	$347,072.85	7,303
2/27/2023	Ourania Tatsis	EVP	Sell	354	$287.48	$101,767.92	56,805
2/27/2023	Stuart A. Arbuckle	COO	Sell	5,034	$287.47	$1,447,123.98	56,556
2/22/2023	Stuart A. Arbuckle	COO	Sell	2,401	$294.33	$706,686.33	66,304
2/13/2023	Ourania Tatsis	EVP	Sell	275	$298.99	$82,222.25	65,765
2/13/2023	Stuart A. Arbuckle	COO	Sell	4,887	$298.92	$1,460,822.04	82,003
2/6/2023	David Altshuler	EVP	Sell	1,304	$306.00	$399,024.00	68,645
1/30/2023	Lloyd Carney	Director	Sell	2,700	$320.52	$865,404.00	4,150
1/27/2023	Yuchun Lee	Director	Sell	1,429	$322.03	$460,180.87	1,875
1/25/2023	Reshma Kewalramani	CEO	Sell	10,000	$315.05	$3,150,500.00	89,598
1/25/2023	Yuchun Lee	Director	Sell	4,000	$313.96	$1,255,840.00	1,875
1/23/2023	Yuchun Lee	Director	Sell	2,129	$312.02	$664,290.58	1,875
1/18/2023	Yuchun Lee	Director	Sell	442	$312.17	$137,979.14	1,875
11/7/2022	David Altshuler	EVP	Sell	1,303	$303.04	$394,861.12	36,077
10/24/2022	Sangeeta N Bhatia	Director	Sell	621	$310.00	$192,510.00	4,040
10/18/2022	Bastiano Sanna	EVP	Sell	1,791	$300.31	$537,855.21	39,192
8/15/2022	Joy Liu	SVP	Sell	3,747	$303.90	$1,138,713.30	9,605
8/15/2022	Reshma Kewalramani	CEO	Sell	11,689	$305.06	$3,565,846.34	99,598
8/15/2022	Stuart A. Arbuckle	COO	Sell	22,173	$303.93	$6,739,039.89	45,278
8/9/2022	Joy Liu	SVP	Sell	946	$300.00	$283,800.00	13,388
8/9/2022	Ourania Tatsis	EVP	Sell	1,400	$298.97	$418,558.00	46,090
8/9/2022	Stuart A. Arbuckle	COO	Sell	5,690	$300.67	$1,710,812.30	60,996
8/8/2022	Sangeeta N Bhatia	Director	Sell	621	$293.03	$181,971.63	4,661
7/29/2022	Sangeeta N Bhatia	Director	Sell	621	$278.77	$173,116.17	5,282
7/25/2022	Jeffrey M. Leiden	Chairman	Sell	132,079	$281.38	$37,164,389.02	2,423
7/19/2022	David Altshuler	EVP	Sell	17,865	$288.65	$5,156,732.25	36,077
6/24/2022	Reshma Kewalramani	CEO	Sell	11,689	$291.30	$3,405,005.70	111,153
5/4/2022	Bastiano Sanna	EVP	Sell	36	$275.09	$9,903.24	41,660
5/2/2022	Bastiano Sanna	EVP	Sell	320	$259.16	$82,931.20	41,696
5/2/2022	Charles F. Wagner, Jr.	CFO	Sell	343	$258.83	$88,778.69	42,730
5/2/2022	Sangeeta N Bhatia	Director	Sell	737	$258.94	$190,838.78	5,903
5/2/2022	Stuart A. Arbuckle	COO	Sell	306	$263.98	$80,777.88	64,760
4/29/2022	Joy Liu	SVP	Sell	120	$275.41	$33,049.20	14,334
4/25/2022	Kristen Ambrose	CAO	Sell	327	$269.55	$88,142.85	3,496
4/18/2022	Yuchun Lee	Director	Sell	2,000	$284.23	$568,460.00	1,875
4/13/2022	Jeffrey M. Leiden	Chairman	Sell	15,789	$289.04	$4,563,652.56	74,160
4/13/2022	Yuchun Lee	Director	Sell	2,000	$287.50	$575,000.00	1,875
4/11/2022	Yuchun Lee	Director	Sell	2,000	$280.30	$560,600.00	1,875
4/7/2022	Bastiano Sanna	EVP	Sell	561	$276.18	$154,936.98	42,782
4/7/2022	Yuchun Lee	Director	Sell	2,000	$274.86	$549,720.00	1,099
4/4/2022	Bastiano Sanna	EVP	Sell	562	$267.71	$150,453.02	43,343
4/4/2022	Yuchun Lee	Director	Sell	2,000	$267.72	$535,440.00	1,875
4/1/2022	Charles F. Wagner, Jr.	CFO	Sell	2,582	$264.76	$683,610.32	43,620
3/31/2022	Margaret G. McGlynn	Director	Sell	5,000	$262.27	$1,311,350.00	1,099
3/17/2022	Charles F. Wagner, Jr.	CFO	Sell	3,171	$250.15	$793,225.65
3/17/2022	Ourania Tatsis	EVP	Sell	2,833	$250.11	$708,561.63
2/25/2022	Ourania Tatsis	EVP	Sell	325	$230.95	$75,058.75
2/18/2022	Ourania Tatsis	EVP	Sell	519	$231.00	$119,889.00
2/11/2022	David Altshuler	EVP	Sell	2,297	$235.02	$539,840.94
2/2/2022	Bastiano Sanna	EVP	Sell	1,040	$250.98	$261,019.20
2/2/2022	Charles F. Wagner, Jr.	CFO	Sell	2,944	$250.07	$736,206.08
1/28/2022	Margaret G. McGlynn	Director	Sell	5,000	$241.79	$1,208,950.00
11/15/2021	Amit Sachdev	EVP	Sell	51	$187.19	$9,546.69
11/15/2021	Stuart A. Arbuckle	COO	Sell	3	$187.26	$561.78
8/19/2021	Reshma Kewalramani	CEO	Buy	10,000	$195.65	$1,956,500.00	69,511
6/2/2021	Sangeeta N. Bhatia	Director	Sell	559	$209.69	$117,216.71	5,465

Elon’s New Device is About to Shock the World

From InvestorPlace | Ad

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/17/2024	Citizens Financial Group Inc. RI	29,374	$12.28M	0.4%	-1.4%	0.011%
5/17/2024	CCM Investment Advisers LLC	29,185	$12.20M	1.5%	N/A	0.011%
5/17/2024	Montchanin Asset Management LLC	10,979	$4.59M	4.5%	N/A	0.004%
5/17/2024	Plato Investment Management Ltd	6,140	$2.57M	0.3%	+677.2%	0.002%
5/17/2024	iA Global Asset Management Inc.	41,032	$17.15M	0.2%	-22.9%	0.016%
5/17/2024	LBP AM SA	1,746	$0.73M	0.0%	-86.3%	0.001%
5/17/2024	Hancock Whitney Corp	2,792	$1.17M	0.0%	+3.8%	0.001%
5/17/2024	Comerica Bank	54,380	$22.73M	0.1%	-6.4%	0.021%
5/17/2024	Tidal Investments LLC	15,082	$6.30M	0.1%	+36.5%	0.006%
5/17/2024	Motley Fool Asset Management LLC	8,521	$3.56M	0.2%	+12.2%	0.003%
5/16/2024	California State Teachers Retirement System	416,962	$174.29M	0.2%	+0.6%	0.162%
5/16/2024	Meiji Yasuda Life Insurance Co	10,582	$4.42M	0.1%	+7.6%	0.004%
5/16/2024	Levin Capital Strategies L.P.	1,071	$0.45M	0.0%	-33.9%	0.000%
5/16/2024	B. Riley Wealth Advisors Inc.	9,443	$3.95M	0.1%	+1.1%	0.004%
5/16/2024	Industrial Alliance Investment Management Inc.	1,774	$0.74M	0.3%	+3.8%	0.001%
5/16/2024	Janus Henderson Group PLC	2,584,315	$1.08B	0.6%	+10.4%	1.001%
5/16/2024	Kennedy Capital Management LLC	8,311	$3.47M	0.1%	N/A	0.003%
5/16/2024	Bayesian Capital Management LP	2,931	$1.23M	0.1%	N/A	0.001%
5/16/2024	Ashford Capital Management Inc.	8,400	$3.51M	0.5%	-10.2%	0.003%
5/16/2024	Caxton Associates LP	5,769	$2.41M	0.1%	-92.5%	0.002%
5/15/2024	Ascent Group LLC	8,617	$3.60M	0.3%	-35.6%	0.003%
5/15/2024	SVB Wealth LLC	17,138	$7.16M	0.2%	-0.3%	0.007%
5/15/2024	Transcendent Capital Group LLC	224	$94K	0.1%	-31.3%	0.000%
5/15/2024	Public Employees Retirement System of Ohio	130,024	$54.35M	0.2%	-6.9%	0.050%
5/15/2024	Public Employees Retirement Association of Colorado	429,782	$179.65M	0.8%	-1.2%	0.167%
5/15/2024	Morse Asset Management Inc	10,195	$4.26M	1.1%	+7.4%	0.004%
5/15/2024	Bellevue Group AG	668,750	$279.54M	4.3%	-9.2%	0.259%
5/15/2024	Kentucky Retirement Systems Insurance Trust Fund	8,504	$3.56M	0.2%	-7.4%	0.003%
5/15/2024	Kentucky Retirement Systems	19,570	$8.18M	0.2%	-5.1%	0.008%
5/15/2024	Price T Rowe Associates Inc. MD	4,493,422	$1.88B	0.2%	-23.7%	1.741%
5/15/2024	BOKF NA	10,232	$4.30M	0.1%	-47.5%	0.004%
5/15/2024	Lazard Asset Management LLC	123,883	$51.78M	0.1%	+3.4%	0.048%
5/15/2024	Epoch Investment Partners Inc.	179,206	$74.91M	0.3%	-50.1%	0.069%
5/15/2024	LRI Investments LLC	458	$0.20M	0.0%	N/A	0.000%
5/15/2024	1832 Asset Management L.P.	5,780	$2.42M	0.0%	-8.1%	0.002%
5/15/2024	Gabelli Funds LLC	22,309	$9.33M	0.1%	-2.1%	0.009%
5/14/2024	Canada Pension Plan Investment Board	386,648	$161.62M	0.2%	+8.0%	0.150%
5/14/2024	JT Stratford LLC	8,670	$3.62M	0.7%	+32.1%	0.003%
5/14/2024	Capital World Investors	25,567,184	$10.69B	1.8%	+17.2%	9.908%
5/14/2024	Capital Research Global Investors	5,743,882	$2.40B	0.5%	+61.0%	2.226%
5/14/2024	Capital International Sarl	116,478	$48.69M	1.6%	+24.5%	0.045%
5/14/2024	Toronto Dominion Bank	152,959	$63.94M	0.1%	+2.0%	0.059%
5/14/2024	Capital International Ltd. CA	99,556	$41.62M	2.0%	+17.3%	0.039%
5/14/2024	Capital International Inc. CA	98,525	$41.18M	0.6%	+26.2%	0.038%
5/14/2024	Capital Group Investment Management PTE. LTD.	21,195	$8.86M	1.6%	+18.2%	0.008%
5/14/2024	Atalanta Sosnoff Capital LLC	168,055	$70.25M	1.6%	-4.3%	0.065%
5/14/2024	Sheaff Brock Investment Advisors LLC	1,193	$0.50M	0.0%	+29.7%	0.000%
5/14/2024	Stamos Capital Partners L.P.	1,210	$0.51M	0.1%	-2.4%	0.000%
5/14/2024	Advisors Asset Management Inc.	21,384	$8.94M	0.2%	+20.6%	0.008%
5/14/2024	Axxcess Wealth Management LLC	2,228	$0.93M	0.0%	+33.6%	0.001%
5/14/2024	EP Wealth Advisors LLC	4,709	$1.97M	0.0%	+4.4%	0.002%
5/14/2024	CreativeOne Wealth LLC	5,450	$2.28M	0.1%	N/A	0.002%
5/14/2024	Delap Wealth Advisory LLC	709	$0.30M	0.1%	N/A	0.000%
5/14/2024	Vident Advisory LLC	51,527	$21.54M	0.4%	+16.6%	0.020%
5/14/2024	Sculati Wealth Management LLC	1,445	$0.60M	0.3%	N/A	0.001%
5/14/2024	Shell Asset Management Co.	17,462	$7.30M	0.3%	+8.1%	0.007%
5/14/2024	Mattern Capital Management LLC	1,299	$0.54M	0.1%	N/A	0.001%
5/14/2024	Crewe Advisors LLC	517	$0.22M	0.0%	N/A	0.000%
5/14/2024	Leelyn Smith LLC	491	$0.21M	0.0%	N/A	0.000%
5/14/2024	MQS Management LLC	961	$0.40M	0.2%	N/A	0.000%
5/14/2024	Natixis	44,638	$18.66M	0.1%	-14.0%	0.017%
5/14/2024	InterOcean Capital Group LLC	1,749	$0.73M	0.0%	+27.5%	0.001%
5/14/2024	Pitcairn Co.	1,937	$0.81M	0.1%	+8.4%	0.001%
5/14/2024	Puzo Michael J	4,613	$1.93M	0.5%	+442.7%	0.002%
5/14/2024	CANADA LIFE ASSURANCE Co	270,222	$113.06M	0.2%	-3.0%	0.105%
5/14/2024	American International Group Inc.	96,351	$40.28M	0.1%	-1.2%	0.037%
5/14/2024	Twin Capital Management Inc.	5,864	$2.45M	0.3%	-5.3%	0.002%
5/14/2024	National Bank of Canada FI	136,133	$57.55M	0.1%	-42.4%	0.053%
5/14/2024	Lake Street Advisors Group LLC	5,221	$2.18M	0.1%	+276.7%	0.002%
5/14/2024	Arjuna Capital	5,957	$2.49M	0.7%	+29.0%	0.002%
5/13/2024	Bessemer Group Inc.	12,605	$5.27M	0.0%	+269.4%	0.005%
5/13/2024	Capitolis Liquid Global Markets LLC	50,000	$20.90M	0.3%	-54.5%	0.019%
5/13/2024	UniSuper Management Pty Ltd	5,832	$2.44M	0.0%	+179.2%	0.002%
5/13/2024	Clearbridge Investments LLC	2,428,455	$1.02B	0.8%	-6.3%	0.941%
5/13/2024	O Shaughnessy Asset Management LLC	19,698	$8.23M	0.1%	+22.6%	0.008%
5/13/2024	Ameritas Investment Partners Inc.	16,509	$6.90M	0.2%	-0.6%	0.006%
5/11/2024	Trustmark National Bank Trust Department	5,374	$2.25M	0.2%	+7.1%	0.002%
5/11/2024	Resurgent Financial Advisors LLC	999	$0.42M	0.2%	+23.3%	0.000%
5/11/2024	Covestor Ltd	408	$0.17M	0.1%	-43.6%	0.000%
5/11/2024	Cynosure Group LLC	1,513	$0.63M	0.1%	N/A	0.001%
5/11/2024	NWK Group Inc.	10,987	$4.59M	2.2%	N/A	0.004%
5/11/2024	Mark Sheptoff Financial Planning LLC	11,346	$4.74M	2.6%	+0.4%	0.004%
5/11/2024	Edgestream Partners L.P.	12,654	$5.29M	0.3%	+1,596.2%	0.005%
5/11/2024	Cercano Management LLC	70,533	$29.48M	0.8%	+0.4%	0.027%
5/10/2024	Ontario Teachers Pension Plan Board	6,772	$2.83M	0.0%	-38.0%	0.003%
5/10/2024	Acadian Asset Management LLC	17,834	$7.44M	0.0%	-3.8%	0.007%
5/10/2024	TIAA Trust National Association	5,348	$2.24M	0.0%	+0.5%	0.002%
5/10/2024	Vanguard Group Inc.	22,676,518	$9.48B	0.2%	+1.8%	8.774%
5/10/2024	Intech Investment Management LLC	20,555	$8.59M	0.1%	+107.0%	0.008%
5/10/2024	Clearstead Trust LLC	137	$57K	0.0%	+104.5%	0.000%
5/10/2024	Nicolet Advisory Services LLC	546	$0.22M	0.0%	-8.5%	0.000%
5/10/2024	Mitsubishi UFJ Trust & Banking Corp	213,590	$89.30M	0.2%	-7.0%	0.083%
5/10/2024	Jupiter Asset Management Ltd.	90,779	$37.95M	0.4%	-44.4%	0.035%
5/10/2024	Te Ahumairangi Investment Management Ltd	14,734	$6.16M	1.1%	+3.3%	0.006%
5/10/2024	Banco Santander S.A.	16,953	$7.09M	0.1%	-16.9%	0.007%
5/10/2024	Wintrust Investments LLC	4,698	$1.96M	0.2%	+149.0%	0.002%
5/10/2024	Cumberland Partners Ltd	29,387	$12.28M	0.9%	N/A	0.011%
5/10/2024	GM Advisory Group LLC	537	$0.22M	0.0%	N/A	0.000%
5/9/2024	Dorsey & Whitney Trust CO LLC	2,364	$0.99M	0.1%	+1.5%	0.001%
5/9/2024	Orion Portfolio Solutions LLC	8,386	$3.51M	0.0%	-16.2%	0.003%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $445.21

$440.35

$446.10

50 Day Range

MA: $409.75

$392.81

$445.21

52 Week Range

Now: $445.21

$320.01

$448.40

Volume

1,382,490 shs

Average Volume

1,120,428 shs

Market Capitalization

$114.89 billion

P/E Ratio

28.89

Dividend Yield

N/A

Beta

0.39

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
David Altshuler (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Carmen Bozic (CMO)
Bastiano Sanna (EVP)
Jeffrey M Leiden (Chairman)
Bruce I Sachs (Director)
Joy Liu (SVP)
Jonathan Biller (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Lloyd Carney (Director)
Yuchun Lee (Director)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Capital World Investors — 9.91%
Vanguard Group Inc. — 8.77%
Capital Research Global Investors — 2.23%
Jennison Associates LLC — 1.85%
Price T Rowe Associates Inc. MD — 1.74%
Janus Henderson Group PLC — 1.00%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Price T Rowe Associates Inc. MD
Los Angeles Capital Management LLC
Epoch Investment Partners Inc.
Clearbridge Investments LLC
Sei Investments Co.
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
Walleye Trading LLC
Bank of New York Mellon Corp
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
David Altshuler (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Carmen Bozic (CMO)
Bastiano Sanna (EVP)
Jeffrey M Leiden (Chairman)
Bruce I Sachs (Director)
Joy Liu (SVP)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
Capital World Investors
Capital Research Global Investors
Jennison Associates LLC
Vanguard Group Inc.
Global Assets Advisory LLC
Janus Henderson Group PLC
ANTIPODES PARTNERS Ltd
Kynam Capital Management LP